Final Programme - World Heart Federation
Final Programme - World Heart Federation
Final Programme - World Heart Federation
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
industry sAteLLite syMPosiA And WorksHoP ACtivities<br />
<strong>Programme</strong> at a glace – satellite symposia table<br />
MONDAy, 19 MAy, 2008 TuESDAy, 20 MAy, 2008<br />
PAVILLION ROOM 12.30 - 13.30 (INTERSESSION) 18.00 - 19.30 (EVENING SESSION) 12.30 - 13.30 (INTERSESSION) 18.00 - 19.30 (EVENING SESSION)<br />
RED<br />
yELLOW<br />
GREEN<br />
Rio de<br />
la Plata<br />
Thames<br />
Danube SyMP<br />
(IS)<br />
Missouri SyMP<br />
(IS)<br />
Nile<br />
SyMP<br />
(IS)<br />
Pilcomayo SyMP<br />
(IS)<br />
Tiber<br />
Mississippi SyMP<br />
(IS)<br />
Tigris<br />
Niger<br />
Ganges<br />
Seine<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
Astra zeneca<br />
Optimising Outcomes in Acute<br />
Coronary Syndromes: Role of New<br />
Approaches to Platelet Inhibition<br />
Bayer Schering Pharma AG<br />
Targeting multiple risk factors to<br />
optimise cardiovascular care<br />
Boston Scientific<br />
Drug Eluting Stent Technology: a<br />
breakthrough in PTCA patient outcome<br />
IFPMA<br />
Transparency around clinical trials and<br />
data: are we on the right trajectory?<br />
Solvay Pharmaceuticals GmbH<br />
Retinopathy associated with prevalent<br />
CHD in patients with T2D. What needs<br />
to be done?<br />
Boehringer Ingelheim GmbH<br />
Acute Myocardial Infarction -<br />
Reperfusion Strategies in Real Life and<br />
their Potential Benefit for the Patient<br />
Abbott Laboratories<br />
Acute <strong>Heart</strong> Failure Treatment: Doing<br />
what comes naturally?<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
Sanofi-aventis Latin America<br />
Intraabdominal Obesity and SyMP<br />
Cardiometabolic Risk Factors: present (IS)<br />
and future<br />
Arrhythmias<br />
<strong>Heart</strong> failure / Left ventricular function<br />
Valvular disease / Pulmonary circulation / Myocardial-pericardial<br />
Ischemia/ Coronary artery disease<br />
Interventions / Peripheral circulation / Stroke<br />
Hypertension<br />
Exercise / Epidemiology / Prevention<br />
Boehringer Ingelheim GmbH<br />
ONTARGET: New Evidence<br />
in Total Cardio & Vascular<br />
Protection<br />
Daiichi Sankyo Brazil<br />
Blood pressure and beyond<br />
- Ancillar effects by AT1 -<br />
Receptor blockade<br />
GlaxoSmithKline<br />
Diabetes, Cardiovascular<br />
disease and Thiazelidinediones<br />
Menarini International<br />
Operations Luxembourg S.A.<br />
From hypertension to heart<br />
failure: the developing role of<br />
vasodilating beta-blockers<br />
American <strong>Heart</strong> Association<br />
Strengthening the Chain<br />
of Survival: From bench to<br />
community<br />
Merck Sharp & Dohme<br />
ER Niacin/Laropiprant: A new<br />
Paradigm in Comprehensive<br />
Lipid Management<br />
Sanofi-aventis<br />
Reshaping the future in the<br />
management of<br />
atrial fibrillation<br />
Pharmacology<br />
Basic science<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
WS<br />
(IS)<br />
SyMP<br />
(IS)<br />
Cardiac imaging / Computers<br />
Acute cardiac care<br />
Paediatric / Congenital heart disease<br />
Nursing / Technician<br />
Public policy / Advocacy initiatives<br />
Pfizer<br />
A Remarkable Change in<br />
Smoking Cessation: Approach<br />
and Treatment<br />
Bayer Schering Pharma AG<br />
Management of right ventricular<br />
dysfunction in pulmonary arterial<br />
hypertension<br />
Novartis Pharma<br />
Emerging Data in the Treatment<br />
of Cardiovascular Disease<br />
Colgate<br />
Oral Health-Cardiovascular<br />
Health: Emerging Evidence of<br />
the Relationship<br />
Biotronik (12.45-13.30)<br />
New Trends in Catheter<br />
Ablation of Atrial Fibrillation<br />
Merck KGaA<br />
The weight of the evidence:<br />
setting the standard with betablockade<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP<br />
(IS)<br />
SyMP (IS) Symposium<br />
GlaxoSmithKiline<br />
Clinical evidence of fondaparinux in<br />
thrombosis: From VTE prevention to<br />
acute coronary syndrome treatment<br />
Janssen-Cilag Farmaceutica<br />
Building New Strategies in Acute<br />
Decompensated <strong>Heart</strong> Failure<br />
Sanofi-aventis<br />
LMWHs Across the Spectrum of<br />
ACS: The Weight of the Evidence<br />
WS (IS) How-to and Workshop session
Change language